EMC Capital Management Sells 924 Shares of United Therapeutics Corporation $UTHR

EMC Capital Management trimmed its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 58.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 653 shares of the biotechnology company’s stock after selling 924 shares during the quarter. EMC Capital Management’s holdings in United Therapeutics were worth $188,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Chung Wu Investment Group LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at $29,000. SVB Wealth LLC bought a new position in United Therapeutics in the first quarter valued at about $32,000. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC acquired a new position in shares of United Therapeutics in the first quarter valued at approximately $60,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $467.55, for a total transaction of $1,870,200.00. Following the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at $60,781.50. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $464.76, for a total transaction of $5,112,360.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,094,337.56. The trade was a 23.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 522,935 shares of company stock valued at $224,478,747. Company insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on UTHR. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Oppenheimer raised their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, UBS Group lifted their target price on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $503.90.

United Therapeutics Stock Up 1.0%

UTHR stock opened at $476.59 on Wednesday. The firm has a market cap of $20.52 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77. The company’s fifty day simple moving average is $435.39 and its 200 day simple moving average is $352.54. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $485.32.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the business posted $6.39 EPS. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.